Vindhya Koneru, MD
Neurology · Houston, TXNPI 1891220612
Payments from drug & device makers
Across 342 payments — averaging $54.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$11K
- AbbVie$1K
- Abbott$1K
- Acadia Pharmaceuticals Inc$619
- Pfizer$462
- Merz Pharmaceuticals, LLC$418
- plus $4K from 34 others
What the payments were for
- Grants$10,00054%
- Travel & lodging$1,1236%
- Food & beverage$7,56240%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 12 | $10,780 |
| AbbVie | 76 | $1,436 |
| Abbott | 18 | $1,256 |
| Acadia Pharmaceuticals Inc | 24 | $619 |
| Pfizer | 39 | $462 |
| Merz Pharmaceuticals, LLC | 17 | $418 |
| Lilly USA, LLC | 20 | $417 |
| Neurocrine Biosciences, Inc. | 17 | $400 |
| Amneal Pharmaceuticals LLC | 14 | $331 |
| SK Life Science, Inc. | 11 | $284 |
| UCB, Inc. | 10 | $244 |
| Teva Pharmaceuticals USA, Inc. | 10 | $235 |
| Eisai Inc. | 9 | $192 |
| Argenx US, Inc. | 6 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $146 |
| Medtronic | 4 | $143 |
| AstraZeneca(2 entities) | 4 | $103 |
| Globus Medical | 1 | $92 |
| Ipsen Biopharmaceuticals, Inc | 3 | $85 |
| Microtransponder, Inc. | 1 | $84 |
| Lundbeck LLC | 4 | $82 |
| Grifols USA, LLC | 3 | $79 |
| Otsuka America Pharmaceutical, Inc. | 4 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $71 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| Corium, LLC | 2 | $52 |
| Averitas Pharma Inc. | 2 | $46 |
| Insightec,inc | 3 | $39 |
| Upsher-smith Laboratories LLC | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| MDD US Operations, LLC | 2 | $31 |
| Si-bone, Inc. | 1 | $29 |
| Livanova USA, Inc. | 2 | $27 |
| Bioventus LLC | 1 | $21 |
| SPR Therapeutics, Inc | 1 | $21 |
| Amgen | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Orphalan Inc | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,692 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $234,427 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 13 | $181,795 |
| NuplazidPimavanserin Tartrate | 21 | $136,679 |
| RytaryCarbidopa/Levodopa | 58 | $98,764 |
| Nurtec OdtRimegepant Sulfate | 17 | $30,088 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $20,074 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 268 | $8,981 |
| Rasagiline Mesylate | 24 | $4,605 |
| Memantine Hcl | 82 | $4,002 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 83 | $3,342 |
| Gabapentin | 231 | $3,054 |
| Levetiracetam | 95 | $2,795 |
| Donepezil Hcl | 256 | $2,751 |
| Quetiapine Fumarate | 113 | $2,387 |
| Propranolol Hcl | 76 | $1,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $400 | $234,42717 claims |
| Acadia Pharmaceuticals IncNuplazid | $619 | $136,67921 claims |
| Amneal Pharmaceuticals LLCRytary | $331 | $98,76458 claims |
| PfizerNurtec Odt | $462 | $30,08817 claims |
| Upsher-smith Laboratories LLCTopiramate | $38 | $58336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.
Other neurology in Houston
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- John LindseyHouston$3.9M
- Joseph KassHouston$3.7M
- William OndoHouston$3.1M
- Vinay PuduvalliHouston$2.5M
- Erin Furr-StimmingHouston$2.1M
- Arjun TarakadHouston$2M
- Mazen DimachkieHouston$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.